Skip to main content

Table 1 Demographic characteristics of healthy controls, positive controls and urologic chronic pelvic pain syndrome patients

From: Hypertension and urologic chronic pelvic pain syndrome: An analysis of MAPP-I data

 

Healthy Controls

Positive Controls

UCPPS

p-value healthy controls vs. UCPPS

p-value

Measure

n = 415

n = 200

n = 424

  

Age (mean (SD))

40.51 (14.07)

41.72 (13.74)

43.37 (15.11)

0.004

0.02

Sex

   

0.73

< 0.001

 Female

233 (56.1)

156 (78.0)

233 (55.0)

  

 Male

182 (43.9)

44 (22.0)

191 (45.0)

  

Race (%)

   

< 0.001

< 0.001

 Asian

24 (5.8)

8 (4.0)

9 (2.1)

  

 Black

48 (11.6)

22 (11.0)

16 (3.8)

  

 Multi Race

12 (2.9)

10 (5.0)

11 (2.6)

  

 Native Hawaiian

0 (0.0)

1 (0.5)

0 (0.0)

  

 Other

11 (2.7)

8 (4.0)

11 (2.6)

  

 Unknown

4 (1.0)

1 (0.5)

3 (0.7)

  

 White

316 (76.1)

150 (75.0)

374 (88.2)

 

Ethnicity (%)

   

0.61

0.55

 Hispanic

35 (8.4)

13 (6.5)

28 (6.6)

  

 Not Hispanic

380 (91.6)

186 (93.0)

395 (93.2)

  

 Unknown

0 (0.0)

1 (0.5)

1 (0.2)

  

Education (%)

   

0.93

0.66

 < High School

2 (0.5)

1 (0.5)

0 (0.0)

  

 High School or GED

27 (6.5)

9 (4.5)

31 (7.3)

  

 Some college

115 (27.7)

66 (33.0)

118 (27.8)

  

 College/university graduate

154 (37.1)

72 (36.0)

163 (38.4)

  

 Graduate or professional school

117 (28.2)

52 (26.0)

112 (26.4)

  

Employment (%)

   

< 0.001

< 0.001

 Disabled

0 (0.0)

25 (12.5)

32 (7.5)

  

 Employed

294 (70.8)

116 (58.0)

278 (65.6)

  

 Full time homemaker

7 (1.7)

7 (3.5)

12 (2.8)

  

 Retired

27 (6.5)

8 (4.0)

43 (10.1)

  

 Unemployed

86 (20.7)

42 (21.0)

58 (13.7)

  

Income (%)

   

< 0.001

< 0.001

 $10,000 or less

44 (10.6)

29 (14.5)

42 (9.9)

  

 $10,001 to $25,000

56 (13.5)

33 (16.5)

34 (8.0)

  

 $25,001 to $50,000

112 (27.0)

49 (24.5)

69 (16.3)

  

 $50,001 to $100,000

120 (28.9)

46 (23.0)

122 (28.8)

  

 Greater than $100,000

53 (12.8)

28 (14.0)

120 (28.3)

  

 Prefer not to answer

30 (7.2)

15 (7.5)

37 (8.7)

  

UCPPS Type

    

 CP/CPPS

 

48 (11.3)

  

 IC/BPS

  

234 (55.2)

  

 Both

  

142 (33.5)

  

Self-Reported Hypertension*

 

0.32

0.21

 No

373 (90.3)

171 (85.5)

372 (88.1)

  

 Yes

40 (9.7)

29 (14.5)

50 (11.9)

  

Antihypertensive Use (%)**

 

0.61

0.87

 No

218 (84.5)

146 (83.4)

322 (83.0)

  

 Yes

40 (15.5)

29 (16.6)

66 (17.0)

  

  Used ACE-I (%)***

21 (52.5)

14 (48.3)

20 (30.3)

0.02

0.252

  Used ARB (%)***

2 (5)

0 (0.0)

15 (22.7)

0.02

0.002

Self-Reported Hypertension and/or Antihypertensive Use (%)***

0.02

0.04

 No

367 (88.4)

166 (83)

350 (82.5)

  

 Yes

48 (11.6)

34 (17.0)

74 (17.5)

  
  1. * Not all patients had available data. Healthy controls n = 413; Positive Controls n = 200; UCPPS n = 422
  2. ** Not all patients had available data. Healthy controls n = 258; Positive Controls n = 175; UCPPS n = 388
  3. *** Denominator used was Antihypertensive use-Yes
  4. **** This number represents a composite of patients who self-reported diagnosis of hypertension and/or use of antihypertensives
  5. Abbreviations: UCPPS: Urologic chronic pelvic pain syndrome; ACE-i: Angiotensin Converting Enzyme Inhibitors; CP/CPPS: Chronic Prostatitis-Chronic Pelvic Pain Syndrome; IC-PBS: Interstitial Cystitis/Bladder Pain Syndrome
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us